URMC Research Network

Find People
Keyword
Last Name
 
More Search Options

Charles Thornton

TitleProfessor
InstitutionSchool of Medicine and Dentistry
DepartmentNeurology
AddressUniversity of Rochester Medical Center
School of Medicine and Dentistry
601 Elmwood Ave, Box 645
Rochester NY 14642
 
 Awards And Honors
1980     Borts Student Research Award
1981     Merck Award for Medical Student Achievement
1987 - 1989Fulbright Senior Lecturing Award
1989 - 1991Awardee, Research Fellowship  | Muscular Dystrophy Association
1991 - 1992Awardee, Experimental Therapeutics Fellowship  | NRSA
1992 - 1997Awardee, Clinical Investigator Development  | NIH/NINDS
1997 - 2000Paul B Beeson Physician Faculty Scholar Award  | American Federation of Aging Research
2010     Norman Saunders Jacob's Ladder International Research Prize
2011     Hans Steinert Award for Myotonic Dystrophy Research
2013     Carrell-Krusen Award  | University of Texas Southwestern, Dallas, TX
 
 Selected Publications
List All   |   Timeline
  1. Heatwole C, Bode R, Johnson N, Dekdebrun J, Dilek N, Heatwole M, Hilbert JE, Luebbe E, Martens W, Mcdermott MP, Rothrock N, Thornton C, Vickrey BG, Victorson D, Moxley R. Myotonic Dystrophy Health Index: Initial evaluation of a disease-specific outcome measure. Muscle Nerve. 2014 Jun; 49(6):906-14.
    View in: PubMed
  2. Axford MM, Wang YH, Nakamori M, Zannis-Hadjopoulos M, Thornton CA, Pearson CE. Detection of Slipped-DNAs at the Trinucleotide Repeats of the Myotonic Dystrophy Type I Disease Locus in Patient Tissues. PLoS Genet. 2013 Dec; 9(12):e1003866.
    View in: PubMed
  3. Nakamori M, Sobczak K, Puwanant A, Welle S, Eichinger K, Pandya S, Dekdebrun J, Heatwole CR, McDermott MP, Chen T, Cline M, Tawil R, Osborne RJ, Wheeler TM, Swanson MS, Moxley RT, Thornton CA. Splicing biomarkers of disease severity in myotonic dystrophy. Ann Neurol. 2013 Dec; 74(6):862-72.
    View in: PubMed
  4. Coonrod LA, Nakamori M, Wang W, Carrell S, Hilton CL, Bodner MJ, Siboni RB, Docter AG, Haley MM, Thornton CA, Berglund JA. Reducing levels of toxic RNA with small molecules. ACS Chem Biol. 2013 Nov 15; 8(11):2528-37.
    View in: PubMed
  5. Rzuczek SG, Gao Y, Tang ZZ, Thornton CA, Kodadek T, Disney MD. Features of modularly assembled compounds that impart bioactivity against an RNA target. ACS Chem Biol. 2013 Oct 18; 8(10):2312-21.
    View in: PubMed
  6. Childs-Disney JL, Stepniak-Konieczna E, Tran T, Yildirim I, Park H, Chen CZ, Hoskins J, Southall N, Marugan JJ, Patnaik S, Zheng W, Austin CP, Schatz GC, Sobczak K, Thornton CA, Disney MD. Induction and reversal of myotonic dystrophy type 1 pre-mRNA splicing defects by small molecules. Nat Commun. 2013 Jun 28; 4:2044.
    View in: PubMed
  7. Hilbert JE, Ashizawa T, Day JW, Luebbe EA, Martens WB, McDermott MP, Tawil R, Thornton CA, Moxley RT. Diagnostic odyssey of patients with myotonic dystrophy. J Neurol. 2013 Oct; 260(10):2497-504.
    View in: PubMed
  8. Vontell R, Supramaniam V, Thornton C, Wyatt-Ashmead J, Mallard C, Gressens P, Rutherford M, Hagberg H. Toll-like receptor 3 expression in glia and neurons alters in response to white matter injury in preterm infants. Dev Neurosci. 2013; 35(2-3):130-9.
    View in: PubMed
  9. Sobczak K, Wheeler TM, Wang W, Thornton CA. RNA Interference Targeting CUG Repeats in a Mouse Model of Myotonic Dystrophy. Mol Ther. 2013 Feb; 21(2):380-7.
    View in: PubMed
  10. Childs-Disney JL, Parkesh R, Nakamori M, Thornton CA, Disney MD. Rational Design of Bioactive, Modularly Assembled Aminoglycosides Targeting the RNA that Causes Myotonic Dystrophy Type 1. ACS Chem Biol. 2012 Dec 21; 7(12):1984-93.
    View in: PubMed
  11. Wheeler TM, Leger AJ, Pandey SK, MacLeod AR, Nakamori M, Cheng SH, Wentworth BM, Bennett CF, Thornton CA. Targeting nuclear RNA for in vivo correction of myotonic dystrophy. Nature. 2012 Aug 2; 488(7409):111-5.
    View in: PubMed
  12. Heatwole C, Bode R, Johnson N, Quinn C, Martens W, McDermott MP, Rothrock N, Thornton C, Vickrey B, Victorson D, Moxley R. Patient-reported impact of symptoms in myotonic dystrophy type 1 (PRISM-1). Neurology. 2012 Jul 24; 79(4):348-57.
    View in: PubMed
  13. Ofori LO, Hoskins J, Nakamori M, Thornton CA, Miller BL. From dynamic combinatorial 'hit' to lead: in vitro and in vivo activity of compounds targeting the pathogenic RNAs that cause myotonic dystrophy. Nucleic Acids Res. 2012 Jul; 40(13):6380-90.
    View in: PubMed
  14. Parkesh R, Childs-Disney JL, Nakamori M, Kumar A, Wang E, Wang T, Hoskins J, Tran T, Housman D, Thornton CA, Disney MD. Design of a bioactive small molecule that targets the myotonic dystrophy type 1 RNA via an RNA motif-ligand database and chemical similarity searching. J Am Chem Soc. 2012 Mar 14; 134(10):4731-42.
    View in: PubMed
  15. Childs-Disney JL, Hoskins J, Rzuczek SG, Thornton CA, Disney MD. Rationally designed small molecules targeting the RNA that causes myotonic dystrophy type 1 are potently bioactive. ACS Chem Biol. 2012 May 18; 7(5):856-62.
    View in: PubMed
  16. Chen CZ, Sobczak K, Hoskins J, Southall N, Marugan JJ, Zheng W, Thornton CA, Austin CP. Two high-throughput screening assays for aberrant RNA-protein interactions in myotonic dystrophy type 1. Anal Bioanal Chem. 2012 Feb; 402(5):1889-98.
    View in: PubMed
  17. Tang ZZ, Yarotskyy V, Wei L, Sobczak K, Nakamori M, Eichinger K, Moxley RT, Dirksen RT, Thornton CA. Muscle weakness in myotonic dystrophy associated with misregulated splicing and altered gating of Ca(V)1.1 calcium channel. Hum Mol Genet. 2012 Mar 15; 21(6):1312-24.
    View in: PubMed
  18. Hilbert JE, Kissel JT, Luebbe EA, Martens WB, McDermott MP, Sanders DB, Tawil R, Thornton CA, Moxley RT. If you build a rare disease registry, will they enroll and will they use it? Methods and data from the National Registry of Myotonic Dystrophy (DM) and Facioscapulohumeral Muscular Dystrophy (FSHD). Contemp Clin Trials. 2012 Mar; 33(2):302-11.
    View in: PubMed
  19. Nakamori M, Thornton C. Muscular dystrophy: A hidden ancestral legacy trumped. Nature. 2011 Oct 6; 478(7367):46-7.
    View in: PubMed
  20. Nakamori M, Gourdon G, Thornton CA. Stabilization of expanded (CTG)•(CAG) repeats by antisense oligonucleotides. Mol Ther. 2011 Dec; 19(12):2222-7.
    View in: PubMed
  21. Mankodi A, Wheeler TM, Shetty R, Salceies KM, Becher MW, Thornton CA. Progressive myopathy in an inducible mouse model of oculopharyngeal muscular dystrophy. Neurobiol Dis. 2012 Jan; 45(1):539-46.
    View in: PubMed
  22. Axford MM, López-Castel A, Nakamori M, Thornton CA, Pearson CE. Replacement of the myotonic dystrophy type 1 CTG repeat with 'non-CTG repeat' insertions in specific tissues. J Med Genet. 2011 Jul; 48(7):438-43.
    View in: PubMed
  23. López Castel A, Nakamori M, Thornton CA, Pearson CE. Identification of restriction endonucleases sensitive to 5-cytosine methylation at non-CpG sites, including expanded (CAG)n/(CTG)n repeats. Epigenetics. 2011 Apr; 6(4):416-20.
    View in: PubMed
  24. Nakamori M, Pearson CE, Thornton CA. Bidirectional transcription stimulates expansion and contraction of expanded (CTG)*(CAG) repeats. Hum Mol Genet. 2011 Feb 1; 20(3):580-8.
    View in: PubMed
  25. Lueck JD, Rossi AE, Thornton CA, Campbell KP, Dirksen RT. Sarcolemmal-restricted localization of functional ClC-1 channels in mouse skeletal muscle. J Gen Physiol. 2010 Dec; 136(6):597-613.
    View in: PubMed
  26. López Castel A, Nakamori M, Tomé S, Chitayat D, Gourdon G, Thornton CA, Pearson CE. Expanded CTG repeat demarcates a boundary for abnormal CpG methylation in myotonic dystrophy patient tissues. Hum Mol Genet. 2011 Jan 1; 20(1):1-15.
    View in: PubMed
  27. Heatwole CR, Eichinger KJ, Friedman DI, Hilbert JE, Jackson CE, Logigian EL, Martens WB, McDermott MP, Pandya SK, Quinn C, Smirnow AM, Thornton CA, Moxley RT. Open-label trial of recombinant human insulin-like growth factor 1/recombinant human insulin-like growth factor binding protein 3 in myotonic dystrophy type 1. Arch Neurol. 2011 Jan; 68(1):37-44.
    View in: PubMed
  28. Logigian EL, Martens WB, Moxley RT, McDermott MP, Dilek N, Wiegner AW, Pearson AT, Barbieri CA, Annis CL, Thornton CA, Moxley RT. Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1. Neurology. 2010 May 4; 74(18):1441-8.
    View in: PubMed
  29. Nakamori M, Thornton C. Epigenetic changes and non-coding expanded repeats. Neurobiol Dis. 2010 Jul; 39(1):21-7.
    View in: PubMed
  30. Logigian EL, Twydell P, Dilek N, Martens WB, Quinn C, Wiegner AW, Heatwole CR, Thornton CA, Moxley RT. Evoked myotonia can be "dialed-up" by increasing stimulus train length in myotonic dystrophy type 1. Muscle Nerve. 2010 Feb; 41(2):191-6.
    View in: PubMed
  31. Du H, Cline MS, Osborne RJ, Tuttle DL, Clark TA, Donohue JP, Hall MP, Shiue L, Swanson MS, Thornton CA, Ares M. Aberrant alternative splicing and extracellular matrix gene expression in mouse models of myotonic dystrophy. Nat Struct Mol Biol. 2010 Feb; 17(2):187-93.
    View in: PubMed
  32. Lee MM, Childs-Disney JL, Pushechnikov A, French JM, Sobczak K, Thornton CA, Disney MD. Controlling the specificity of modularly assembled small molecules for RNA via ligand module spacing: targeting the RNAs that cause myotonic muscular dystrophy. J Am Chem Soc. 2009 Dec 2; 131(47):17464-72.
    View in: PubMed
  33. Mueller CM, Hilbert JE, Martens W, Thornton CA, Moxley RT, Greene MH. Hypothesis: neoplasms in myotonic dystrophy. Cancer Causes Control. 2009 Dec; 20(10):2009-20.
    View in: PubMed
  34. Warf MB, Nakamori M, Matthys CM, Thornton CA, Berglund JA. Pentamidine reverses the splicing defects associated with myotonic dystrophy. Proc Natl Acad Sci U S A. 2009 Nov 3; 106(44):18551-6.
    View in: PubMed
  35. Klooster R, Straasheijm K, Shah B, Sowden J, Frants R, Thornton C, Tawil R, van der Maarel S. Comprehensive expression analysis of FSHD candidate genes at the mRNA and protein level. Eur J Hum Genet. 2009 Dec; 17(12):1615-24.
    View in: PubMed
  36. Nakamori M, Sobczak K, Moxley RT, Thornton CA. Scaled-down genetic analysis of myotonic dystrophy type 1 and type 2. Neuromuscul Disord. 2009 Nov; 19(11):759-62.
    View in: PubMed
  37. Mulders SA, van den Broek WJ, Wheeler TM, Croes HJ, van Kuik-Romeijn P, de Kimpe SJ, Furling D, Platenburg GJ, Gourdon G, Thornton CA, Wieringa B, Wansink DG. Triplet-repeat oligonucleotide-mediated reversal of RNA toxicity in myotonic dystrophy. Proc Natl Acad Sci U S A. 2009 Aug 18; 106(33):13915-20.
    View in: PubMed
  38. Welle S, Burgess K, Thornton CA, Tawil R. Relation between extent of myostatin depletion and muscle growth in mature mice. Am J Physiol Endocrinol Metab. 2009 Oct; 297(4):E935-40.
    View in: PubMed
  39. Pushechnikov A, Lee MM, Childs-Disney JL, Sobczak K, French JM, Thornton CA, Disney MD. Rational design of ligands targeting triplet repeating transcripts that cause RNA dominant disease: application to myotonic muscular dystrophy type 1 and spinocerebellar ataxia type 3. J Am Chem Soc. 2009 Jul 22; 131(28):9767-79.
    View in: PubMed
  40. Wheeler TM, Sobczak K, Lueck JD, Osborne RJ, Lin X, Dirksen RT, Thornton CA. Reversal of RNA dominance by displacement of protein sequestered on triplet repeat RNA. Science. 2009 Jul 17; 325(5938):336-9.
    View in: PubMed
  41. Osborne RJ, Lin X, Welle S, Sobczak K, O'Rourke JR, Swanson MS, Thornton CA. Transcriptional and post-transcriptional impact of toxic RNA in myotonic dystrophy. Hum Mol Genet. 2009 Apr 15; 18(8):1471-81.
    View in: PubMed
  42. Gareiss PC, Sobczak K, McNaughton BR, Palde PB, Thornton CA, Miller BL. Dynamic combinatorial selection of molecules capable of inhibiting the (CUG) repeat RNA-MBNL1 interaction in vitro: discovery of lead compounds targeting myotonic dystrophy (DM1). J Am Chem Soc. 2008 Dec 3; 130(48):16254-61.
    View in: PubMed
  43. Sorenson EJ, Windbank AJ, Mandrekar JN, Bamlet WR, Appel SH, Armon C, Barkhaus PE, Bosch P, Boylan K, David WS, Feldman E, Glass J, Gutmann L, Katz J, King W, Luciano CA, McCluskey LF, Nash S, Newman DS, Pascuzzi RM, Pioro E, Sams LJ, Scelsa S, Simpson EP, Subramony SH, Tiryaki E, Thornton CA. Subcutaneous IGF-1 is not beneficial in 2-year ALS trial. Neurology. 2008 Nov 25; 71(22):1770-5.
    View in: PubMed
  44. A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. Neurology. 2008 Aug 5; 71(6):394-9.
    View in: PubMed
  45. Osborne RJ, Thornton CA. Cell-free cloning of highly expanded CTG repeats by amplification of dimerized expanded repeats. Nucleic Acids Res. 2008 Mar; 36(4):e24.
    View in: PubMed
  46. Ciafaloni E, Mignot E, Sansone V, Hilbert JE, Lin L, Lin X, Liu LC, Pigeon WR, Perlis ML, Thornton CA. The hypocretin neurotransmission system in myotonic dystrophy type 1. Neurology. 2008 Jan 15; 70(3):226-30.
    View in: PubMed
  47. Welle S, Tawil R, Thornton CA. Sex-related differences in gene expression in human skeletal muscle. PLoS One. 2008; 3(1):e1385.
    View in: PubMed
  48. Yadava RS, Frenzel-McCardell CD, Yu Q, Srinivasan V, Tucker AL, Puymirat J, Thornton CA, Prall OW, Harvey RP, Mahadevan MS. RNA toxicity in myotonic muscular dystrophy induces NKX2-5 expression. Nat Genet. 2008 Jan; 40(1):61-8.
    View in: PubMed
  49. Wheeler TM, Lueck JD, Swanson MS, Dirksen RT, Thornton CA. Correction of ClC-1 splicing eliminates chloride channelopathy and myotonia in mouse models of myotonic dystrophy. J Clin Invest. 2007 Dec; 117(12):3952-7.
    View in: PubMed
  50. Wheeler TM, Thornton CA. Myotonic dystrophy: RNA-mediated muscle disease. Curr Opin Neurol. 2007 Oct; 20(5):572-6.
    View in: PubMed
  51. Moxley RT, Logigian EL, Martens WB, Annis CL, Pandya S, Moxley RT, Barbieri CA, Dilek N, Wiegner AW, Thornton CA. Computerized hand grip myometry reliably measures myotonia and muscle strength in myotonic dystrophy (DM1). Muscle Nerve. 2007 Sep; 36(3):320-8.
    View in: PubMed
  52. Yuan Y, Compton SA, Sobczak K, Stenberg MG, Thornton CA, Griffith JD, Swanson MS. Muscleblind-like 1 interacts with RNA hairpins in splicing target and pathogenic RNAs. Nucleic Acids Res. 2007; 35(16):5474-86.
    View in: PubMed
  53. Logigian EL, Ciafaloni E, Quinn LC, Dilek N, Pandya S, Moxley RT, Thornton CA. Severity, type, and distribution of myotonic discharges are different in type 1 and type 2 myotonic dystrophy. Muscle Nerve. 2007 Apr; 35(4):479-85.
    View in: PubMed
  54. Rudnicki DD, Holmes SE, Lin MW, Thornton CA, Ross CA, Margolis RL. Huntington's disease--like 2 is associated with CUG repeat-containing RNA foci. Ann Neurol. 2007 Mar; 61(3):272-82.
    View in: PubMed
  55. Wheeler TM, Krym MC, Thornton CA. Ribonuclear foci at the neuromuscular junction in myotonic dystrophy type 1. Neuromuscul Disord. 2007 Mar; 17(3):242-7.
    View in: PubMed
  56. Lueck JD, Mankodi A, Swanson MS, Thornton CA, Dirksen RT. Muscle chloride channel dysfunction in two mouse models of myotonic dystrophy. J Gen Physiol. 2007 Jan; 129(1):79-94.
    View in: PubMed
  57. Osborne RJ, Welle S, Venance SL, Thornton CA, Tawil R. Expression profile of FSHD supports a link between retinal vasculopathy and muscular dystrophy. Neurology. 2007 Feb 20; 68(8):569-77.
    View in: PubMed
  58. Welle S, Bhatt K, Pinkert CA, Tawil R, Thornton CA. Muscle growth after postdevelopmental myostatin gene knockout. Am J Physiol Endocrinol Metab. 2007 Apr; 292(4):E985-91.
    View in: PubMed
  59. Lueck JD, Lungu C, Mankodi A, Osborne RJ, Welle SL, Dirksen RT, Thornton CA. Chloride channelopathy in myotonic dystrophy resulting from loss of posttranscriptional regulation for CLCN1. Am J Physiol Cell Physiol. 2007 Apr; 292(4):C1291-7.
    View in: PubMed
  60. Osborne RJ, Thornton CA. RNA-dominant diseases. Hum Mol Genet. 2006 Oct 15; 15 Spec No 2:R162-9.
    View in: PubMed
  61. Kanadia RN, Shin J, Yuan Y, Beattie SG, Wheeler TM, Thornton CA, Swanson MS. Reversal of RNA missplicing and myotonia after muscleblind overexpression in a mouse poly(CUG) model for myotonic dystrophy. Proc Natl Acad Sci U S A. 2006 Aug 1; 103(31):11748-53.
    View in: PubMed
  62. Lin X, Miller JW, Mankodi A, Kanadia RN, Yuan Y, Moxley RT, Swanson MS, Thornton CA. Failure of MBNL1-dependent post-natal splicing transitions in myotonic dystrophy. Hum Mol Genet. 2006 Jul 1; 15(13):2087-97.
    View in: PubMed
  63. Udd B, Meola G, Krahe R, Thornton C, Ranum LP, Bassez G, Kress W, Schoser B, Moxley R. 140th ENMC International Workshop: Myotonic Dystrophy DM2/PROMM and other myotonic dystrophies with guidelines on management. Neuromuscul Disord. 2006 Jun; 16(6):403-13.
    View in: PubMed
  64. Gallo JM, Jin P, Thornton CA, Lin H, Robertson J, D'Souza I, Schlaepfer WW. The role of RNA and RNA processing in neurodegeneration. J Neurosci. 2005 Nov 9; 25(45):10372-5.
    View in: PubMed
  65. Mankodi A, Lin X, Blaxall BC, Swanson MS, Thornton CA. Nuclear RNA foci in the heart in myotonic dystrophy. Circ Res. 2005 Nov 25; 97(11):1152-5.
    View in: PubMed
  66. Logigian EL, Blood CL, Dilek N, Martens WB, Moxley RT, Wiegner AW, Thornton CA, Moxley RT. Quantitative analysis of the "warm-up" phenomenon in myotonic dystrophy type 1. Muscle Nerve. 2005 Jul; 32(1):35-42.
    View in: PubMed
  67. Berg J, Jiang H, Thornton CA, Cannon SC. Truncated ClC-1 mRNA in myotonic dystrophy exerts a dominant-negative effect on the Cl current. Neurology. 2004 Dec 28; 63(12):2371-5.
    View in: PubMed
  68. Jiang H, Mankodi A, Swanson MS, Moxley RT, Thornton CA. Myotonic dystrophy type 1 is associated with nuclear foci of mutant RNA, sequestration of muscleblind proteins and deregulated alternative splicing in neurons. Hum Mol Genet. 2004 Dec 15; 13(24):3079-88.
    View in: PubMed
  69. Logigian EL, Moxley RT, Blood CL, Barbieri CA, Martens WB, Wiegner AW, Thornton CA, Moxley RT. Leukocyte CTG repeat length correlates with severity of myotonia in myotonic dystrophy type 1. Neurology. 2004 Apr 13; 62(7):1081-9.
    View in: PubMed
  70. Welle S, Brooks AI, Delehanty JM, Needler N, Bhatt K, Shah B, Thornton CA. Skeletal muscle gene expression profiles in 20-29 year old and 65-71 year old women. Exp Gerontol. 2004 Mar; 39(3):369-77.
    View in: PubMed
  71. Kanadia RN, Johnstone KA, Mankodi A, Lungu C, Thornton CA, Esson D, Timmers AM, Hauswirth WW, Swanson MS. A muscleblind knockout model for myotonic dystrophy. Science. 2003 Dec 12; 302(5652):1978-80.
    View in: PubMed
  72. A comparison of muscle strength testing techniques in amyotrophic lateral sclerosis. Neurology. 2003 Dec 9; 61(11):1503-7.
    View in: PubMed
  73. Mankodi A, Teng-Umnuay P, Krym M, Henderson D, Swanson M, Thornton CA. Ribonuclear inclusions in skeletal muscle in myotonic dystrophy types 1 and 2. Ann Neurol. 2003 Dec; 54(6):760-8.
    View in: PubMed
  74. Bachinski LL, Udd B, Meola G, Sansone V, Bassez G, Eymard B, Thornton CA, Moxley RT, Harper PS, Rogers MT, Jurkat-Rott K, Lehmann-Horn F, Wieser T, Gamez J, Navarro C, Bottani A, Kohler A, Shriver MD, Sallinen R, Wessman M, Zhang S, Wright FA, Krahe R. Confirmation of the type 2 myotonic dystrophy (CCTG)n expansion mutation in patients with proximal myotonic myopathy/proximal myotonic dystrophy of different European origins: a single shared haplotype indicates an ancestral founder effect. Am J Hum Genet. 2003 Oct; 73(4):835-48.
    View in: PubMed
  75. Udd B, Meola G, Krahe R, Thornton C, Ranum L, Day J, Bassez G, Ricker K. Report of the 115th ENMC workshop: DM2/PROMM and other myotonic dystrophies. 3rd Workshop, 14-16 February 2003, Naarden, The Netherlands. Neuromuscul Disord. 2003 Sep; 13(7-8):589-96.
    View in: PubMed
  76. Welle S, Brooks AI, Delehanty JM, Needler N, Thornton CA. Gene expression profile of aging in human muscle. Physiol Genomics. 2003 Jul 7; 14(2):149-59.
    View in: PubMed
  77. Welle S, Bhatt K, Shah B, Needler N, Delehanty JM, Thornton CA. Reduced amount of mitochondrial DNA in aged human muscle. J Appl Physiol. 2003 Apr; 94(4):1479-84.
    View in: PubMed
  78. Thornton CA, Welle SL. Molecular fingerprints of inflammatory myopathies. Neurology. 2002 Oct 22; 59(8):1128-9.
    View in: PubMed
  79. Mankodi A, Thornton CA. Myotonic syndromes. Curr Opin Neurol. 2002 Oct; 15(5):545-52.
    View in: PubMed
  80. Wolfe GI, Barohn RJ, Foster BM, Jackson CE, Kissel JT, Day JW, Thornton CA, Nations SP, Bryan WW, Amato AA, Freimer ML, Parry GJ. Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravis. Muscle Nerve. 2002 Oct; 26(4):549-52.
    View in: PubMed
  81. Welle S, Brooks AI, Thornton CA. Computational method for reducing variance with Affymetrix microarrays. BMC Bioinformatics. 2002 Aug 30; 3:23.
    View in: PubMed
  82. Mankodi A, Takahashi MP, Jiang H, Beck CL, Bowers WJ, Moxley RT, Cannon SC, Thornton CA. Expanded CUG repeats trigger aberrant splicing of ClC-1 chloride channel pre-mRNA and hyperexcitability of skeletal muscle in myotonic dystrophy. Mol Cell. 2002 Jul; 10(1):35-44.
    View in: PubMed
  83. Welle S, Bhatt K, Shah B, Thornton C. Insulin-like growth factor-1 and myostatin mRNA expression in muscle: comparison between 62-77 and 21-31 yr old men. Exp Gerontol. 2002 Jun; 37(6):833-9.
    View in: PubMed
  84. Meola G, Sansone V, Marinou K, Cotelli M, Moxley RT, Thornton CA, De Ambroggi L. Proximal myotonic myopathy: a syndrome with a favourable prognosis? J Neurol Sci. 2002 Jan 15; 193(2):89-96.
    View in: PubMed
  85. Fougerousse F, Durand M, Lopez S, Suel L, Demignon J, Thornton C, Ozaki H, Kawakami K, Barbet P, Beckmann JS, Maire P. Six and Eya expression during human somitogenesis and MyoD gene family activation. J Muscle Res Cell Motil. 2002; 23(3):255-64.
    View in: PubMed
  86. Mankodi A, Urbinati CR, Yuan QP, Moxley RT, Sansone V, Krym M, Henderson D, Schalling M, Swanson MS, Thornton CA. Muscleblind localizes to nuclear foci of aberrant RNA in myotonic dystrophy types 1 and 2. Hum Mol Genet. 2001 Sep 15; 10(19):2165-70.
    View in: PubMed
  87. Musser WS, Barbano RL, Thornton CA, Moxley RT, Herrmann DN, Logigian EL. Distal myasthenia gravis with a decrement, an increment, and denervation. J Clin Neuromuscul Dis. 2001 Sep; 3(1):16-9.
    View in: PubMed
  88. Rose MR, McDermott MP, Thornton CA, Palenski C, Martens WB, Griggs RC. A prospective natural history study of inclusion body myositis: implications for clinical trials. Neurology. 2001 Aug 14; 57(3):548-50.
    View in: PubMed
  89. Tapscott SJ, Thornton CA. Biomedicine. Reconstructing myotonic dystrophy. Science. 2001 Aug 3; 293(5531):816-7.
    View in: PubMed
  90. Welle S, Brooks A, Thornton CA. Senescence-related changes in gene expression in muscle: similarities and differences between mice and men. Physiol Genomics. 2001 Mar 8; 5(2):67-73.
    View in: PubMed
  91. Mendell JR, Barohn RJ, Freimer ML, Kissel JT, King W, Nagaraja HN, Rice R, Campbell WW, Donofrio PD, Jackson CE, Lewis RA, Shy M, Simpson DM, Parry GJ, Rivner MH, Thornton CA, Bromberg MB, Tandan R, Harati Y, Giuliani MJ. Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology. 2001 Feb 27; 56(4):445-9.
    View in: PubMed
  92. Mankodi A, Logigian E, Callahan L, McClain C, White R, Henderson D, Krym M, Thornton CA. Myotonic dystrophy in transgenic mice expressing an expanded CUG repeat. Science. 2000 Sep 8; 289(5485):1769-73.
    View in: PubMed
  93. Miller JW, Urbinati CR, Teng-Umnuay P, Stenberg MG, Byrne BJ, Thornton CA, Swanson MS. Recruitment of human muscleblind proteins to (CUG)(n) expansions associated with myotonic dystrophy. EMBO J. 2000 Sep 1; 19(17):4439-48.
    View in: PubMed
  94. Nolan PM, Peters J, Strivens M, Rogers D, Hagan J, Spurr N, Gray IC, Vizor L, Brooker D, Whitehill E, Washbourne R, Hough T, Greenaway S, Hewitt M, Liu X, McCormack S, Pickford K, Selley R, Wells C, Tymowska-Lalanne Z, Roby P, Glenister P, Thornton C, Thaung C, Stevenson JA, Arkell R, Mburu P, Hardisty R, Kiernan A, Erven A, Steel KP, Voegeling S, Guenet JL, Nickols C, Sadri R, Nasse M, Isaacs A, Davies K, Browne M, Fisher EM, Martin J, Rastan S, Brown SD, Hunter J. A systematic, genome-wide, phenotype-driven mutagenesis programme for gene function studies in the mouse. Nat Genet. 2000 Aug; 25(4):440-3.
    View in: PubMed
  95. Welle S, Bhatt K, Thornton CA. High-abundance mRNAs in human muscle: comparison between young and old. J Appl Physiol. 2000 Jul; 89(1):297-304.
    View in: PubMed
  96. Forbes GB, Griggs RC, Moxley RT, Thornton CT, Tawil R. K-40 and dual-energy X-ray absorptiometry estimates of lean weight compared. Normals and patients with neuromuscular disease. Ann N Y Acad Sci. 2000 May; 904:111-4.
    View in: PubMed
  97. Heyderman RS, Thornton C, Mielke J, Curtis N, Thorniley MS, Green CJ, Newton DE, Pasvol G. Adults with cerebral malaria do not have sensory evoked responses typical of deep general anaesthesia. Trans R Soc Trop Med Hyg. 2000 Mar-Apr; 94(2):182-4.
    View in: PubMed
  98. Tian B, White RJ, Xia T, Welle S, Turner DH, Mathews MB, Thornton CA. Expanded CUG repeat RNAs form hairpins that activate the double-stranded RNA-dependent protein kinase PKR. RNA. 2000 Jan; 6(1):79-87.
    View in: PubMed
  99. Wax PM, Thornton CA. Recovery from severe arsenic-induced peripheral neuropathy with 2,3-dimercapto-1-propanesulphonic acid. J Toxicol Clin Toxicol. 2000; 38(7):777-80.
    View in: PubMed
  100. Meola G, Sansone V, Perani D, Colleluori A, Cappa S, Cotelli M, Fazio F, Thornton CA, Moxley RT. Reduced cerebral blood flow and impaired visual-spatial function in proximal myotonic myopathy. Neurology. 1999 Sep 22; 53(5):1042-50.
    View in: PubMed
  101. Schwid SR, Thornton CA, Pandya S, Manzur KL, Sanjak M, Petrie MD, McDermott MP, Goodman AD. Quantitative assessment of motor fatigue and strength in MS. Neurology. 1999 Sep 11; 53(4):743-50.
    View in: PubMed
  102. Welle S, Bhatt K, Thornton CA. Inventory of high-abundance mRNAs in skeletal muscle of normal men. Genome Res. 1999 May; 9(5):506-13.
    View in: PubMed
  103. A controlled trial of recombinant methionyl human BDNF in ALS: The BDNF Study Group (Phase III). Neurology. 1999 Apr 22; 52(7):1427-33.
    View in: PubMed
  104. Welle S, Bhatt K, Thornton CA. Stimulation of myofibrillar synthesis by exercise is mediated by more efficient translation of mRNA. J Appl Physiol. 1999 Apr; 86(4):1220-5.
    View in: PubMed
  105. Kester RC, Antrum R, Thornton CA, Ramsden CH, Harding I. A comparison of teicoplanin versus cephradine plus metronidazole in the prophylaxis of post-operative infection in vascular surgery. J Hosp Infect. 1999 Mar; 41(3):233-43.
    View in: PubMed
  106. Mezei MM, Mankodi A, Brais B, Marineau C, Thornton CA, Rouleau GA, Karpati G. Minimal expansion of the GCG repeat in the PABP2 gene does not predispose to sporadic inclusion body myositis. Neurology. 1999 Feb; 52(3):669-70.
    View in: PubMed
  107. Thornton C. The myotonic dystrophies. Semin Neurol. 1999; 19(1):25-33.
    View in: PubMed
  108. Thornton CA, Ashizawa T. Getting a grip on the myotonic dystrophies. Neurology. 1999 Jan 1; 52(1):12-3.
    View in: PubMed
  109. Thornton C, Snowden MA, Carling D. Identification of a novel AMP-activated protein kinase beta subunit isoform that is highly expressed in skeletal muscle. J Biol Chem. 1998 May 15; 273(20):12443-50.
    View in: PubMed
  110. Simmons Z, Thornton CA, Seltzer WK, Richards CS. Relative stability of a minimal CTG repeat expansion in a large kindred with myotonic dystrophy. Neurology. 1998 May; 50(5):1501-4.
    View in: PubMed
  111. Welle S, Thornton CA. High-protein meals do not enhance myofibrillar synthesis after resistance exercise in 62- to 75-yr-old men and women. Am J Physiol. 1998 Apr; 274(4 Pt 1):E677-83.
    View in: PubMed
  112. Welle S, Thornton C. Insulin-like growth factor-I, actin, and myosin heavy chain messenger RNAs in skeletal muscle after an injection of growth hormone in subjects over 60 years old. J Endocrinol. 1997 Oct; 155(1):93-7.
    View in: PubMed
  113. Welle S, Thornton C, Bhatt K, Krym M. Expression of elongation factor-1 alpha and S1 in young and old human skeletal muscle. J Gerontol A Biol Sci Med Sci. 1997 Sep; 52(5):B235-9.
    View in: PubMed
  114. Thornton CA, Wymer JP, Simmons Z, McClain C, Moxley RT. Expansion of the myotonic dystrophy CTG repeat reduces expression of the flanking DMAHP gene. Nat Genet. 1997 Aug; 16(4):407-9.
    View in: PubMed
  115. Welle S, Totterman S, Thornton C. Effect of age on muscle hypertrophy induced by resistance training. J Gerontol A Biol Sci Med Sci. 1996 Nov; 51(6):M270-5.
    View in: PubMed
  116. Welle S, Thornton C, Statt M, McHenry B. Growth hormone increases muscle mass and strength but does not rejuvenate myofibrillar protein synthesis in healthy subjects over 60 years old. J Clin Endocrinol Metab. 1996 Sep; 81(9):3239-43.
    View in: PubMed
  117. Thornton CA, Welle S, Griggs RC, Abraham GN. Human IgG production in vivo: determination of synthetic rate by nonradioactive tracer incorporation. J Immunol. 1996 Jul 15; 157(2):950-5.
    View in: PubMed
  118. Welle S, Bhatt K, Thornton C. Polyadenylated RNA, actin mRNA, and myosin heavy chain mRNA in young and old human skeletal muscle. Am J Physiol. 1996 Feb; 270(2 Pt 1):E224-9.
    View in: PubMed
  119. Welle S, Thornton C, Totterman S, Forbes G. Utility of creatinine excretion in body-composition studies of healthy men and women older than 60 y. Am J Clin Nutr. 1996 Feb; 63(2):151-6.
    View in: PubMed
  120. Thornton C, Griggs RC, Moxley RT. PROMM syndrome (Ricker's disease) Ann Neurol. 1995 Aug; 38(2):273.
    View in: PubMed
  121. Welle S, Thornton C, Statt M. Myofibrillar protein synthesis in young and old human subjects after three months of resistance training. Am J Physiol. 1995 Mar; 268(3 Pt 1):E422-7.
    View in: PubMed
  122. Rifai Z, Welle S, Kamp C, Thornton CA. Ragged red fibers in normal aging and inflammatory myopathy. Ann Neurol. 1995 Jan; 37(1):24-9.
    View in: PubMed
  123. Welle S, Thornton C, Statt M, McHenry B. Postprandial myofibrillar and whole body protein synthesis in young and old human subjects. Am J Physiol. 1994 Oct; 267(4 Pt 1):E599-604.
    View in: PubMed
  124. Smith JP, Doll D, Croitoru R, Thornton C, Perry MC. Octreotide has no effect on advanced colon cancer. J Clin Gastroenterol. 1994 Apr; 18(3):245-7.
    View in: PubMed
  125. Thornton CA, Griggs RC, Moxley RT. Myotonic dystrophy with no trinucleotide repeat expansion. Ann Neurol. 1994 Mar; 35(3):269-72.
    View in: PubMed
  126. Houston S, Thornton C, Emmanuel J, Latif A. Human T cell lymphotropic virus type 1 in Zimbabwe. Trans R Soc Trop Med Hyg. 1994 Mar-Apr; 88(2):170-2.
    View in: PubMed
  127. Thornton CA, Griggs RC. Plasma exchange and intravenous immunoglobulin treatment of neuromuscular disease. Ann Neurol. 1994 Mar; 35(3):260-8.
    View in: PubMed
  128. Thornton CA, Johnson K, Moxley RT. Myotonic dystrophy patients have larger CTG expansions in skeletal muscle than in leukocytes. Ann Neurol. 1994 Jan; 35(1):104-7.
    View in: PubMed
  129. Welle S, Thornton C, Jozefowicz R, Statt M. Myofibrillar protein synthesis in young and old men. Am J Physiol. 1993 May; 264(5 Pt 1):E693-8.
    View in: PubMed
  130. Jackson C, Beumont PJ, Thornton C, Lennerts W. Dreams of death: Von Weizsäcker's Dreams in so-called endogenic anorexia: a research note. Int J Eat Disord. 1993 Apr; 13(3):329-32.
    View in: PubMed
  131. Thornton CA, Ballow M. Safety of intravenous immunoglobulin. Arch Neurol. 1993 Feb; 50(2):135-6.
    View in: PubMed
  132. Thornton CA, Houston S, Latif AS. Neurocysticercosis and human immunodeficiency virus infection. A possible association. Arch Neurol. 1992 Sep; 49(9):963-5.
    View in: PubMed
  133. Neves O, Stein CM, Thornton C, Gangaidzo I, Thomas JE. Rhabdomyolysis associated with human immunodeficiency virus (HIV) infection. Cent Afr J Med. 1991 Nov; 37(11):387-8.
    View in: PubMed
  134. Thornton CA, Latif AS, Emmanuel JC. Guillain-Barré syndrome associated with human immunodeficiency virus infection in Zimbabwe. Neurology. 1991 Jun; 41(6):812-5.
    View in: PubMed

Visualizations


Thornton's Networks

Concepts
_
Co-Authors
_
Similar People
_
Same Department